About the Company
We do not have any company description for Astria Therapeutics Inc at the moment.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ATXS News
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for ...
Astria Therapeutics Reports Positive Initial Results From ALPHA-STAR Trial - Quick Facts
Astria Therapeutics, Inc. (ATXS) reported positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial ...
Buy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial Results
Analyst Michael Higgins of Ladenburg Thalmann & Co. maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a ...
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
Key Insights Significantly high institutional ownership implies Astria Therapeutics' stock price is sensitive to ...
Astria Therapeutics Inc ATXS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, on Track for Expected IND Submission by Year-End 2024 and Phase 1a Initiation in Q1 2025 -- Astria Therapeutics, ...
Astria Therapeutics (NASDAQ: CATB)
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary ...
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
The webcast will be archived for 90 days. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families ...
Astria Therapeutics Inc (ATXS)
Investing.com - Astria Therapeutics (NASDAQ: ATXS) reported first quarter EPS of $-0.720, $0.03 worse than the analyst estimate of $-0.690. Revenue for the quarter ...
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported ...
Loading the latest forecasts...